|
Ocuscience |
|
|
May 19, 2014 Issue |
||
|
The Most Powerful Name In Corporate News and Information |
||
|
Precision Ophthalmic Devices for Ophthalmic and Visual Science Communities |
||
 Daniel
LindgrenCEO Daniel Lindgren is the president of OcuScience®, a precision ophthalmic device manufacturer with operations in Missouri and Nevada. He holds a Bachelors degree in Economics from Missouri University of Science & Technology, and a Masters in International Business from the Boeing Institute, Saint Louis University. Mr. Lindgren also completed the Kauffman Entrepreneurial Internship Program.
Daniel has extensive experience in a variety of industries including management consulting, aviation maintenance, medical device development, manufacturing, and pharmaceutical science. He is a member of the International Society of Clinical Electrophysiology of Vision (ISCEV), and also collaborates with several universities on eye research.
Mr. Lindgren volunteer activities include founding Member at Large for the Mid-America Medical Reserve Corps, and is also a member of Lions International. He is a veteran US Army Military Police Officer. Daniel is married with three children and lives in Henderson, Nevada.
About OcuScience OcuScience® develops and distributes precision ophthalmic devices for the ophthalmic and visual science communities.
Our mission is to meet the challenging requirements of our partners with the highest quality devices, accessories, and support. “We are a company focused on discovery. We have our eye on the different methodologies and future drugs, therapeutics, and devices that are coming forward to help cure blindness.” - Daniel Lindgren |
Suite 262 Henderson, NV 89014
866.250.3937
|
|
|
Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – May 19, 2014
CEOCFO: Mr. Lindgren, what is OcuScience? Mr. Lindgren: OcuScience is focused on developing and commercializing precision ophthalmic devices. We are a privately held company established in 2006. Our primary objective is to facilitate “Discoveries In Sight.” We provide a line of products and services that support basic research all the way to commercialization.
CEOCFO: Would you tell us a little about the main products and maybe something that is a little more unusual? Mr. Lindgren: Our product line covers ophthalmic imaging and electrophysiology as well as novel drug delivery systems to the eye. Our ophthalmic imaging systems are used to study the retina and the visual pathway. We are able to discern, on a cellular level, what is happening in both the progression of diseases as well as the therapeutic effect of drugs on the retina and the visual pathway.
The electrophysiology devices measure the effect disease has on the ability of the retina to turn light into vision and determine if a drug therapy is helping or protecting the eye from insults. The device can also help determine whether the drug therapy has an effect on the ability to repair damage to the eye. Our equipment is also used in veterinary ophthalmology in the care of our pets.
We support customers that primarily work in three fields to fight blindness, which are: neuro-protection of the retina and the eye, restoration of the cellular structures as in gene therapeutics, and replacement strategies like stem cells as possible cures.
CEOCFO: What is the competitive landscape? Are there similar products? Mr. Lindgren: The landscape for us is that we are very focused on the discovery phase. The cornerstone of our company is to provide excellent instrumentation for basic research as well as developing new and innovative processes in ophthalmological research. We provide the tools to tell the researchers if their biologics are working as expected; that they are working in a safe manner, and to confirm, on a quantitative level, that they are effective. The nice thing about our devices is that we have developed systems that test drugs in ways that allow repeated tests over time. Our instruments can collect multiple time points that help determine whether a drug therapy is safe and effective while reducing the number of laboratory animals needed to prove scientific significance.
CEOCFO: What are you able to find with your technology? Mr. Lindgren: OcuScience products are well established and used throughout the industry and can be found in most major research institutions for the study of laboratory animals. Our devices measure the ability of the retina to turn light into electrical energy that is sent down the visual pathway. The researchers introduce a therapy to an animal model to see if it is functionally repaired or not.
We also have devices that image the cellular structures in the eye down to 1.5 microns. We provide researchers unprecedented information about what is happening to the cells over time in the presence of various therapies.
CEOCFO: What is it about the equipment is it that allows you to see to that depth? Mr. Lindgren: Our devices use the power of optical coherence tomography, which is a very precise laser that can visualize the cellular structures in the eye. That laser energy is then reflected back to our device as spectral light. From that signal, the device creates a microscopic cross sectional image where the thinnest layers of cells can be seen.
CEOCFO: Do researchers look for OcuScience equipment? Do they know the name? Mr. Lindgren: Yes. OcuScience is our registered brand. We have several products that have been in the market for eight years and we have more products launching this year. We are looking at robust growth through commercializing new technologies that have not been available up until now. We are expanding our brand to include the iVIVO® system. “iVIVO” provides the means to examine cellular structures “in vivo” (examining a living animal) which has major benefits of being able to study the progression of disease and also pin points therapeutic affect over a longer period of time. This is a fantastic improvement that will help bring safe drugs to the market quicker.
CEOCFO: Are you able to tell us about the newer products? Mr. Lindgren: We have one product that allows us to test drugs on human donor retinas. We will then be able to confirm that the drugs are safe in human tissue before any clinical human trials are run.
CEOCFO: How wide is the ophthalmic research industry? Mr. Lindgren: The Association for Research of Vision and Ophthalmology (ARVO) has nearly 15,000 members. Nearly half of our devices are exported to other parts of the world.
CEOCFO: Do you find that being a US company carries weight in other countries? Mr. Lindgren: It certainly does help to be a company based in the United States. We have a very good presence in the research community here in the United States as well as internationally.
CEOCFO: How do you decide which products to work on developing? Mr. Lindgren: At the heart of it, we are an engineering company. We are always in pursuit of what is new and what is next. We work with researchers and help them define how our equipment can best serve their application, and in many times, there are certain unique aspects of their research that have potential commercial value. We will work to continue to develop those ideas into commercial products.
CEOCFO: What surprised you as OcuScience has grown and developed new concepts and products? Mr. Lindgren: I do not know if it is a surprise but it is incredibly satisfying that we are adding value to eye research and helping human kind.
CEOCFO: Why pay attention to OcuScience? What sets you apart?
Mr. Lindgren:
We are a company focused on discovery. We have our eye on the different
methodologies and future drugs, therapeutics, and devices that are coming
forward to help cure blindness. We have our hands on what is happening in
this industry and the eye research community. |
||
|
|
||
|
|
||
|
Ophthalmic Devices, Ocuscience, Healthcare Companies, CEO Interviews 2014, Daniel Lindgren, Precision Ophthalmic Devices for Ophthalmic and Visual Science Communities, ophthalmic imaging and electrophysiology products, novel drug delivery systems to the eye, Recent CEO Interviews, developers, distributers of precision ophthalmic devices, facilitate Discoveries In Sight, we provide a line of products and services that support basic research all the way to commercialization, our ophthalmic imaging systems are used to study the retina and the visual pathway, we are able to discern, on a cellular level, what is happening in both the progression of diseases as well as the therapeutic effect of drugs on the retina and the visual pathway, the electrophysiology devices measure the effect disease has on the ability of the retina to turn light into vision and determine if a drug therapy is helping or protecting the eye from insults, the device can also help determine whether the drug therapy has an effect on the ability to repair damage to the eye, our equipment is also used in veterinary ophthalmology in the care of our pets, we support customers that primarily work in three fields to fight blindness, which are: neuro-protection of the retina and the eye, restoration of the cellular structures as in gene therapeutics, and replacement strategies like stem cells as possible cures, Ocuscience Press Releases, News, Healthcare Stock, Medical Device Stocks, Companies looking for venture capital, Angel Investors, private companies looking for investors, healthcare companies seeking investors, medical device companies needing investment capital |
||
